Cidofovir: Difference between revisions

From IDWiki
()
()
 
(4 intermediate revisions by the same user not shown)
Line 1: Line 1:
==Background==
==Background==


*Acyclic nucleoside phosphonate that competes with cytosine nucleotides to inhibit viral DNA polymerase
*Cytosine nucleotide analogue that inhibits DNA polymerase in [[human herpesviruses]]
*Indications: {{#ask: [[Is treated by::cidofovir]] | default=none}}
*Indications: {{#ask: [[Is treated by::cidofovir]] | default=none}}


Line 12: Line 12:


*Unlike [[ganciclovir]], it does ''not'' need phosphorylation by UL97
*Unlike [[ganciclovir]], it does ''not'' need phosphorylation by UL97
*Does not penetrate CSF


==Dosing==
==Dosing==
Line 19: Line 20:
==Safety==
==Safety==


*Major adverse effect is [[Adverse drug reaction::irreversible renal tubular necrosis]], which may be prevented by [[probenecid]]
*Major adverse effect is dose-dependent, irreversible [[Adverse drug reaction::renal tubular necrosis]], which may be prevented by [[probenecid]]
**Contraindicated when creatinine >132 μmol/L, CrCl <55 mL/min, or urine protein ≥100 mg/dL (2+ proteinuria)
*[[Neutropenia]]
*Acute [[iritis]]


[[Category:Antivirals]]
[[Category:Acyclic nucleoside phosphonates]]

Latest revision as of 23:14, 14 September 2020

Background

Spectrum of Activity

Pharmacokinetics and Pharmacodynamics

  • Unlike ganciclovir, it does not need phosphorylation by UL97
  • Does not penetrate CSF

Dosing

  • Should be given with probenecid 2 g IV prior to each dose

Safety

  • Major adverse effect is dose-dependent, irreversible renal tubular necrosis, which may be prevented by probenecid
    • Contraindicated when creatinine >132 μmol/L, CrCl <55 mL/min, or urine protein ≥100 mg/dL (2+ proteinuria)
  • Neutropenia
  • Acute iritis